Nabla

2020-10-27

The French digital care company, Nabla, in researching GPT-3’s capabilities for medical documentation, diagnosis support, and treatment recommendation, found its inconsistency and lack of scientific and medical expertise unviable and risky in healthcare applications. This incident has been downgraded to an issue as it does not meet current ingestion criteria.